BridgeBio Pharma LLC bought BBOT
October 10, 2025 · Form 4 insider transaction
BridgeBio Pharma LLC bought 784,720 shares of BridgeBio Oncology Therapeutics, Inc., a transaction worth N/A. The trade was recorded as j and disclosed on an SEC Form 4, filed 6 days after the transaction.
Footnotes
Shares issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025 in exchange for additional financial and accounting support services provided through December 31, 2025.; Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collectively, the "BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any.; (Continued from Footnote 2) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.